Evocatal and RohnerChem combine their complementary services to offer customers a seamless solution for the development of high-performance biocatalytic processes
and their rapid application in the synthesis of fine chemicals and API.
The focus of this strategic partnership is to offer highly innovative routes to enantiomerically pure products, to realize the most cost-competitive process for a customer product from the beginning and to reduce commercialization timelines. The
preferred but non-exclusive partnership will allow customers to benefit from the synergy of Evocatal`s premium services in development and supply of tailored enzymes and RohnerChem`s unique process development and upscaling capabilities.
The Evocatal enzyme universe consists of a variety of Ketoreductases, C-C-coupling enzymes, Esterases, Transaminases, Hydroxynitrilases and others which allow access to almost all functional groups in very cost competitive processes and with ee values almost always close to 100 %.
For enantiomerically pure products for which the process is not yet available, Evocatal can quickly develop and produce tailored enzymes which will be applied in RohnerChem`s pilot plant and production equipment. The experience of RohnerChem in asymmetric hydrogenations and other complementary technologies ensures that really the most economic process will be selected in this partnership.
Customers will have to deal with only one project manager to reduce complexity and maximise service levels.
“The technologies and capabilities of evocatal and RohnerChem match excellently”, says Dr. Michael Puls, Managing Director of evocatal. “By combining the chemical technologies and scale-up abilities of RohnerChem with the high efficiency of our biocatalysis platforms we can provide most comprehensive services and create great value for our customers.”
Dr Andreas Meudt, Sales & Marketing Director of RohnerChem, commented: “Our cooperation with the Evocatal enzyme experts completes the RohnerChem offering in state-of-the-art synthesis methods and allows us to ensure that our customers get the best process in the shortest possible timeframe - with Swiss precision in upscaling.”
Financial terms of the partnership were not disclosed.
Solvias and RohnerChem announce partnership for custom research and manufacturing services
Solvias and RohnerChem announced a partnership for custom research and manufacturing services. The preferred but non-exclusive partnership closes the chain of services from route scouting through to commercial manufacturing. Customers will benefit from the synergy of Solvias’ expertise in c ... more
Rockwood Holdings, Inc. Divests Rohner AG to Arques Industries AG
Rockwood Holdings, Inc. announced that its subsidiary Groupe Novasep SAS has divested its Rohner AG business to Arques Industries AG of Germany for an undisclosed amount. Rohner AG operates a state-of-the-art, cGMP-compliant facility in Pratteln, Switzerland, that manufactures advanced inte ... more
The company founder, Joseph Rohner, believed that ongoing change was vital to progress. And it is a philosophy that our 200 highly skilled staff uphold to the present day - from the production of formic acid, to the development and global marketing of textile dyes, state-of-the-art performa ... more
evocatal draws two new investors as it closes €3.5m Series B round
evocatal GmbH has completed a Series B financing round. All of the company's existing investors took part, along with new investors NRW.BANK and LANXESS. In realizing the next step of its growth strategy, evocatal has partnered with two new investors: LANXESS and NRW.BANK. The investments f ... more
evoxx technologies GmbH, a German Industrial Biotechnology Company, is focusing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bioconversion. With its proprietary enzymes and carbohydrate ingredients, evoxx is active in high ... more
